Horizon Pharma PLC
Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?
Horizon Therapeutics (HZNP) is up 23.13%, and BioMarin (BMRN) is down 6.62% year-to-date. Let’s study the drivers and risks for both these rare disease players in greater detail.
Analysts Raise Target Price for Horizon Pharma in March
Wall Street analysts expect an upside potential of 11.65% for Horizon Pharma (HZNP) based on the company’s closing price on March 25.
Why Shire Stock Rose in the Week Ended March 29
On March 29, 2018, Shire (SHPG) was trading at $149.39, which represented a 21% rise from its 52-week low of $123.73.
A Deeper Look at Valeant Pharmaceuticals’ Recent Financial Performance
In 3Q16, Valeant Pharmaceuticals (VRX) generated revenues of $2.4 billion, compared with $2.2 billion in 3Q17.
Inside Valeant Pharmaceuticals’ Recent Divestments
Valeant Pharmaceuticals (VRX) was granted the worldwide exclusive licensing rights for manufacturing and selling the EyeGate 2 delivery system.
Valeant Pharmaceuticals on the Street: Analyst Ratings This February
Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating.
How Analysts Rated Jazz Pharmaceuticals in December
In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.
Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17
In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.
Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017
In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.
What Are Analysts Saying about Horizon Pharma?
According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”
Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug
Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.
Gauging the Performance of Horizon Pharma’s Rayos in 3Q16
During the third quarter of 2016, Rayos, a delayed-release prednisone, rose 15.0% to $13.4 million compared to 3Q15.
How Did Horizon Pharma Perform in 3Q16?
In 3Q16, Horizon Pharma’s (HZNP) net sales on a GAAP basis fell to $208.7 million. Non-GAAP net sales were $273.7 million.
Factors behind Horizon Pharma’s Volatility in December
With the Express Scripts agreement, Horizon Pharma’s net sales in 2017 are expected to rise. The probability of a top-line expansion has boosted investor sentiment.
Horizon Pharma’s Steep Fall in December: What Happened?
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.
Why Neurocrine Biosciences May See Higher Losses in 2016
Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.
Procysbi: Major Addition to Horizon’s Orphan Drug Portfolio
According to Horizon Pharma’s (HZNP) estimates, Procysbi holds a peak sales potential of more than $300 million.
Buy Allows Horizon to Further Expand into Orphan Drug Space
Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.
News of Acquisition Caused Horizon Pharma Stock to Rise
The market was pleased with the merger deal between Horizon Pharma (HZNP) and Raptor Pharmaceuticals. HZNP shares rose to $18.89 on September 12.
How the Numbers Add Up for the Horizon Pharma–Raptor Deal
According to the September 12, 2016, agreement between Horizon Pharma (HZNP) and Raptor Pharmaceuticals, HZNP will acquire Raptor common stock at $9 per share.
Understanding the Growth Drivers behind Horizon’s Rheumatology Business Unit
Horizon Pharma’s Rheumatology portfolio includes Rayos, or Lodotra, and Krystexxa. Rayos is indicated for rheumatoid arthritis, PMR, and Lupus.
What Are the Prospects for Horizon’s Primary Care Segment?
Horizon Pharma’s Primary Care division is the company’s largest revenue contributor and grew by 33% on a yearly basis in 2Q16.
Inside Horizon’s Orphan and Rheumatology Business Unit
Multiple acquisitions have helped Horizon expand its portfolio into orphan drugs and rheumatology. Now it has a total of nine drugs under its umbrella.
What’s Really Driving Horizon’s Valuation?
In 1Q16, Horizon Pharm’s sales on a YoY basis grew by 81% to $205 million. During that period, its adjusted EBITDA jumped annually by 122% to $72 million.
The Truth behind Horizon’s EV-to-EBITDA Performance
On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.
Positive Top-Line Data May Help Secure FDA Approval for Valbenazine
Neurocrine Biosciences has seen positive results from Kinect 3, a phase-3 trial that tested the efficacy and safety of Valbenazine for tardive dyskinesia.
Inside Neurocrine Biosciences’ Analyst Recommendations in 2016
Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.
The Facts behind the Valeant Drug Pricing Controversy
Valeant Pharmaceuticals International (VRX) significantly raised the prices of two of its heart drugs—Nitropress and Isuprel—which caused a controversy and an outrage.
Mid-Cap Stock Update: Horizon Tanks 21% on Earnings Concerns
In the mid-cap space, Horizon Pharma (HZNP) was the worst hit, falling by 21% for the week ended April 15, 2016.
Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva
Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages
Anacor Pharmaceuticals: $250 Million in Convertible Senior Notes
Anacor Pharmaceuticals rose 7.8% and closed at $61.51 on April 4, 2016. It was trading above its 20-day moving average. Year-to-date, the stock has fallen 45.6%.
Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know
Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.
Introducing Krystexxa, the Latest Addition to Horizon’s Orphan Portfolio
In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.
Why Actimmune, Horizon’s Lead Orphan Product, Has Such Huge Potential
After the Vidara merger in September 2014, Horizon Pharma gained access to Actimmune, which has been approved by the FDA for CGD and SMO.
Inside the Performance of Horizon’s Primary Care Division
In fiscal 4Q15, Horizon’s Primary Care sales rose by more than 125%. The growth of the division was primarily driven by volume rather than by price.
How Horizon Became a Growth Stock
Over the past 18 months, Horizon Pharma has acquired three orphan drugs. The acquisition of Hyperion Therapeutics in May 2015 gave it Ravicti and Buphenyl.
Why Is Horizon Trading at a Premium on a Price-to-Sales Basis?
On March 24, Horizon Pharma was trading at a forward PS multiple of 2.18x. It appears to be trading at a premium next to Valeant, Mallinckrodt, and Endo.
IBB Leads Biotech ETFs with Rise of 3.1%
Markets rose in the week ended November 20, as many believed the FED will hike the interest rate in December. The iShares Nasdaq Biotechnology ETF (IBB) rose 3.1%.
Horizon Rose and Outperformed IBB’s Mid-Cap Stocks
Horizon Pharma rose 5.4% on November 16, 2015. The stock rose due to the update at the shareholder meeting regarding the Depomed acquisition.
ISIS Leads the Mid-Cap Space, Stock Rises by 12.3%
ISIS Pharmaceuticals rose by 12.3% as it announced 3Q15 earnings. ISIS reported revenue of $49.1 million as compared to $44.1 million in 3Q14.
More QE, Cheaper Euro Will Benefit Investors in European Equity
European equity was rising, even outperforming major developed markets, in the first half of 2015. But the Greece debt crisis and China’s stock market crash pulled back the surge.
IBB Remained Flat Last Week
The iShares Nasdaq Biotechnology ETF (IBB) gained marginally by 0.57% in the week ending September 18, 2015.
IBB ADRs Outperform Benchmark for August 10–17, 2015
The iShares NASDAQ Biotechnology ETF (IBB) has 14 American Depository Receipts (ADR) in its portfolio. These ADRs have a weight of 9.36% and gave an average return of 0.85% for August 10–17, 2015.
IBB’s American Depository Receipts Underperformed
The iShares Nasdaq Biotechnology ETF (IBB) has 14 ADRs in its portfolio with a weight of 9.36%. Although XBI provides exposure to ADRs, it’s very limited.
Horizon Pharma’s Specialty Business Unit in 2Q15
As per a company press release, Horizon Pharma’s (HZNP) specialty business unit consists of two products: RAYOS and Lodotra.
Horizon Pharma Appears to Be on an Acquisition Spree
Horizon Pharma (HZNP), after acquiring Vidara Therapeutics on September 19, 2014, completed its second acquisition of Hyperion Therapeutics (HPTX) on May 7, 2015.
Biotech ETF Provides Exposure to International Stocks
The iShares Nasdaq Biotechnology ETF (IBB) has exposure to 14 international stocks, with a weight of 9.36%. For the week ended July 24, the average return of these shares was -2.13%.